Noticias

News

IMG_9298_2

Vecmedical

Vecmedical at the National Congress of Surgery in Milano

We have attended the National Surgery Congress in Milano to present the news we are working on, as well as the products in our portfolio.

Products

COOLINGBIS. New surgical dissecting sealer for soft tissues

COOLINGBIS is a monopolar radiofrequency (RF) electrosurgical electrode, with a unique internally cooled electrode design (patented technology) for haemostatic sealing, coagulation and cutting (in models with included blade) of soft tissue. It is ideal for total or partial resection of organs such as the liver, kidneys, pancreas, and spleen.

Due to its unique technology and versatility COOLINGBIS allows for greater surgical safety, facilitating the surgical resection of soft tissues and drastically reducing intraoperative bleeding.

Coagulation is performed by means of a metal electrode located at the distal end, with a rounded tip, electrically connected to a radiofrequency generator.

The active electrode contains a closed hydraulic circuit with cold saline that is driven to the distal end by a continuous perfusion pump. The flow of cold saline keeps the surface of the tissue below 100 °C, constantly cooling the active electrode.

The refrigerated saline circulates within the electrode without ever touching the patient’s tissue, which increases product safety. Some similar device-produced incidents are due to burns in surgical area created by heated irrigated saline.

Long and short models allow for use in laparoscopy and laparotomy, respectively.

Surgical safety. Clinical benefits

Clinical results of the COOLINGBIS device prove the following benefits:

  1. Complication reduction: It reduces the need for clamping manoeuvres (thus reducing the associated ischemia) and surgery time1.
  2. Lower need of transfusion: COOLINGBIS’s great coagulation power drastically reduces blood loss. COOLINGBIS has proven to be particularly effective in the laparoscopic approach1,2.
  3. Shorter postoperative time: Hospital stay becomes significantly shorter1 (from 11 to 6 days).
  4. Reduction of local hepatic recurrence: It allows to create a deep thermal injury which may reduce local hepatic recurrence. In patients treated with COOLINGBIS local recurrence was 0 % (vs 27 % in the control group), in an average follow-up of more than 2 years3. The research suggests that liver transection using COOLINGBIS (which is capable of producing deep thermal lesions) may reduce local liver recurrence, especially in case of margin invasion (positive margin).
  5. Fistula control: COOLINGBIS reduces the risk of biliary fistulas as the coagulative necrosis plane allows optimal sealing of vessels and ducts. Reduces the incidence of postoperative pancreatic fistula4,5.
  6. Reduces the need for renal clamping in partial nephrectomies.

 

Manufactured by Vecmedical, distribution in Spain: Mercé V.

  1. Burdio, F. et al. A new single-instrument technique for parenchyma division and hemostasis in liver resection: A clinical feasibility study. Am. J. Surg. 200, e75–e80 (2010).
  2. Quesada, R. et al. Impact of monopolar radiofrequency coagulation on intraoperative blood loss during liver resection: a prospective randomised controlled trial. Int. J. Hyperth. 33, 135–141 (2017).
  3. Quesada, R. et al. The impact of radiofrequency-assisted transection on local hepatic recurrence after resection of colorectal liver metastases. Surg. Oncol. 26, 229–235 (2017).
  4. Stavrou, G. A., Donati, M., Fruehauf, N. R., Flemming, P. & Oldhafer, K. J. Liver resection using heat coagulative necrosis: Indications and limits of a new method. ANZ J. Surg. 79, 624–628 (2009).
  5. Weber, J. C. et al. New technique for liver resection using heat coagulative necrosis. Ann. Surg. 236, 560–563 (2002).

See product

IMG_8701

New Opportunities

Catalonia Bio & Health Tech Innovation Group

Catalonia Bio & Health Tech Innovation Workgroup has started to foster company-hospital cooperation and market Access.

Vecmedical is present as one of the Leaders of this Workgroup, with the Presence of its CEO, Angel Alonso, also member of the Board of Catalonia Bio & Health Tech.